NetworkNewsBreaks – Karuna Therapeutics, Inc. (NASDAQ: KRTX) Featured in Mizuho Securities Research Report
Karuna Therapeutics (NASDAQ: KRTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We had the opportunity to host investor meetings with the management team of Karuna Therapeutics, including CEO Steve Paul and CFO Troy Ignezi. As expected, investors were mainly focused on the progress Karuna is making in moving lead asset KarXT into Phase 3 development for the treatment of acute psychosis in patients with schizophrenia. However, investors are also clearly looking into KarXT's potential to move into additional indications, most notably dementia-related psychosis. We present our key takeaways from the…







